MeiraGTx Holdings PLC
MGTX6.590USD
+0.099+1.54%
Market hours （ET）Quotes delayed by 15 min
516.64MMarket Cap
LossP/E TTM
More Details of MeiraGTx Holdings PLC Company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Company Info
Company codeMGTX
Company nameMeiraGTx Holdings PLC
IPO dateJun 08, 2018
Founded at2018
CEODr. Alexandria Forbes, Ph.D.
Number of employees381
Security typeOrdinary Share
Fiscal year-endJun 08
Address450 East 29Th Street
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10016
Phone16468607985
Websitehttps://meiragtx.com/
Company codeMGTX
IPO dateJun 08, 2018
Founded at2018
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.41M
-3.26%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
972.65K
-2.41%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
+4.44%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.00K
+150.00%
Amb. Martin Indyk, Ph.D.
Amb. Martin Indyk, Ph.D.
Independent Director
Independent Director
35.00K
+133.33%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.41M
-3.26%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
972.65K
-2.41%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
+4.44%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.00K
+150.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, Apr 11
Update time: Fri, Apr 11
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Perceptive Advisors LLC
15.95%
Sanofi
15.47%
Johnson & Johnson Innovation-JJDC, Inc.
8.42%
Adage Capital Management, L.P.
6.38%
Prosight Capital
5.57%
Other
48.20%
Shareholder Statistics
Shareholder
Proportion
Perceptive Advisors LLC
15.95%
Sanofi
15.47%
Johnson & Johnson Innovation-JJDC, Inc.
8.42%
Adage Capital Management, L.P.
6.38%
Prosight Capital
5.57%
Other
48.20%
Type
Shareholder
Proportion
Hedge Fund
20.60%
Corporation
20.50%
Private Equity
15.95%
Venture Capital
8.42%
Investment Advisor
7.03%
Investment Advisor/Hedge Fund
5.71%
Individual Investor
4.36%
Research Firm
1.07%
Bank and Trust
0.09%
Other
16.28%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
230
77.61M
98.43%
+22.67M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
2022Q4
257
33.39M
69.27%
-47.74K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
12.58M
15.95%
--
--
Dec 31, 2024
Sanofi
12.20M
15.47%
+12.20M
--
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.42%
--
--
Dec 31, 2024
Adage Capital Management, L.P.
5.03M
6.38%
-194.52K
-3.72%
Dec 31, 2024
Prosight Capital
4.39M
5.57%
-509.73K
-10.40%
Dec 31, 2024
Adena Estate Inc.
3.27M
4.14%
+3.27M
--
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
2.64M
3.35%
+278.31K
+11.79%
Dec 31, 2024
683 Capital Management LLC
2.42M
3.06%
-135.00K
-5.29%
Dec 31, 2024
Woodline Partners LP
1.54M
1.95%
+1.54M
--
Dec 31, 2024
Forbes (Alexandria)
1.46M
1.85%
+58.91K
+4.21%
Feb 21, 2025
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.54%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.54%
iShares Micro-Cap ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.03%
SPDR S&P International Small Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data